Treatment Response and Duration of Therapy in Transplant-Ineligible NDMM
Closing out their module on transplant-ineligible NDMM management, expert panelists consider best practices regarding duration of therapy and adjustments to drug regimens.
Selecting the Optimal Therapy for Patients With Transplant-Ineligible NDMM
Comprehensive discussion on the array of treatment regimens available for patients with transplant-ineligible NDMM and how best to sequence therapy.
Patient Case 3: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Expert oncologists focus on a final patient case of transplant-ineligible newly diagnosed multiple myeloma and reflect on the treatment armamentarium in this setting.
Transplant-Eligible NDMM: Optimizing Therapy for Efficacy and Tolerability
Before closing out their review of treatment for transplant-eligible multiple myeloma, panelists consider how they might adjust therapy to optimize tolerability or efficacy.
Selecting Induction Therapy for Patients With High-Risk Transplant-Eligible NDMM
Shared insight on the optimal selection of induction therapy for patients with high-risk transplant-eligible newly diagnosed multiple myeloma.
Patient Case 2: High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma
Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists define high-risk disease and how it impacts treatment.
Consolidation and Maintenance Therapy in Transplant-Eligible NDMM
A brief discussion on the use of consolidation therapy to improve patient outcomes following transplant in newly diagnosed multiple myeloma.
Selecting the Optimal Induction Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma
Expert perspectives on the real-world use of induction therapy and transplant in patients with transplant-eligible newly diagnosed multiple myeloma.
Recent Updates on Treatment Options for Patients With Transplant-Eligible NDMM
Comprehensive insight on induction therapy regimens in transplant-eligible newly diagnosed multiple myeloma based on the GRIFFIN, MASTER, and DETERMINATION clinical studies.
Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma
Expert panelists review the case of transplant-eligible newly diagnosed multiple myeloma and consider optimal selection of induction therapy.
2 Commerce Drive Cranbury, NJ 08512